BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/24/2015 11:11:00 AM | Browse: 1051 | Download: 2083
 |
Received |
|
2015-06-03 10:15 |
|
Peer-Review Started |
|
2015-06-03 16:38 |
|
To Make the First Decision |
|
2015-08-26 13:53 |
|
Return for Revision |
|
2015-08-27 16:52 |
|
Revised |
|
2015-09-03 11:43 |
|
Second Decision |
|
2015-10-12 16:33 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2015-10-20 09:18 |
|
Articles in Press |
|
2015-10-20 09:18 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2015-11-23 14:41 |
|
Typeset the Manuscript |
|
2015-12-10 09:13 |
|
Publish the Manuscript Online |
|
2015-12-24 11:11 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
| Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yoshimasa Saito, Hiroshi Serizawa, Yukako Kato, Masaru Nakano, Masahiko Nakamura, Hidetsugu Saito, Hidekazu Suzuki and Takanori Kanai |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Research Grant of Kitasato Institute Hospital |
|
|
| Corresponding Author |
Yoshimasa Saito, MD, PhD, Division of Pharmacotherapeutics, Keio University Faculty of Pharmacy, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512,
Japan. saito-ys@pha.keio.ac.jp
|
| Key Words |
CYP2C19; Esomeprazole; Helicobacter pylori; Pepsinogen; Proton pump inhibitor |
| Core Tip |
Esomeprazole (EPZ) is considered to be more effective for inhibition of gastric acid secretion than other first-generation proton pump inhibitors (PPIs) because its metabolism is not influenced by CYP2C19 genotype. In the present study, however, first-line eradication by EPZ-based triple therapy for patients with Helicobacter pylori (H. pylori)-positive gastritis was influenced by CYP2C19 genotype, and the eradication rate was on the same level with triple therapies with other first-generation PPIs in the Japanese population. Unlike previous studies, our results suggest that there is no advantage for EPZ-based triple therapy on H. pylori eradication in comparison with other first-generation PPIs.
|
| Publish Date |
2015-12-24 11:11 |
| Citation |
Saito Y, Serizawa H, Kato Y, Nakano M, Nakamura M, Saito H, Suzuki H, Kanai T. First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype. World J Gastroenterol 2015; 21(48): 13548-13554 |
| URL |
http://www.wjgnet.com/1007-9327/full/v21/i48/13548.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v21.i48.13548 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
